Elite Pharmaceuticals, Inc. (ELI) Announces Supplemental Application For Site Transfer Of Isradipine
3/24/2014 8:56:12 AM
NORTHVALE, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.
Help employers find you! Check out all the jobs and post your resume.
comments powered by